Related Experiment Video
Updated: Sep 8, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma
Martin Perez-Santos1, Maricruz Anaya-Ruiz2, Donaciano Flores-Robles3
1Innovation and Knowledge Transfer Department, Benemerita Autonomous University of Puebla, Puebla, México.
Introduction:
Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment.
Areas Covered:
Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated in vitro cytotoxicity in tumor cells through increased proliferation of CD4+ and CD8+ cells, and the release of IFN-γ, IL-2, and TNF-α, as well as efficacy in a mouse model of multiple myeloma.
Expert Opinion:
Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

